The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose‐intensive chemotherapy including rituximab

Summary The introduction of Rituximab has improved the outcome and survival rates of Burkitt lymphoma (BL). However, early relapse and refractoriness are current limitations of BL treatment and new biological factors affecting the outcome of these patients have not been explored. This study aimed to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2016-02, Vol.172 (3), p.428-438
Hauptverfasser:	Forero‐Castro, Maribel, Robledo, Cristina, Lumbreras, Eva, Benito, Rocio, Hernández‐Sánchez, Jesús M., Hernández‐Sánchez, María, García, Juan L., Corchete‐Sánchez, Luis A., Tormo, Mar, Barba, Pere, Menárguez, Javier, Ribera, Jordi, Grande, Carlos, Escoda, Lourdes, Olivier, Carmen, Carrillo, Estrella, García de Coca, Alfonso, Ribera, Josep‐María, Hernández‐Rivas, Jesús M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use array‐based comparative genomic hybridization (aCGH) Burkitt lymphoma Burkitt Lymphoma - drug therapy Burkitt Lymphoma - genetics Chromosome Aberrations Comparative Genomic Hybridization - methods Female Genome High-Throughput Nucleotide Sequencing - methods Humans Kaplan-Meier Estimate Male Middle Aged next‐generation sequencing outcome Prognosis rituximab Rituximab - administration & dosage Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!